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Oxford, Oxford, United Kingdom
bJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the NetherlandsAbstractPrediction models are developed to aid health care providers in estimating the probability or risk that a specific disease or condition is present
(diagnosticmodels)or that a specificeventwill occur in the future (prognosticmodels), to inform their decisionmaking.However, the overwhelming
evidence shows that the quality of reporting of predictionmodel studies is poor. Only with full and clear reporting of information on all aspects of a
predictionmodel can riskof bias andpotential usefulness of predictionmodels be adequately assessed.TheTransparentReporting of amultivariable
predictionmodel for Individual Prognosis OrDiagnosis (TRIPOD) Initiative developed a set of recommendations for the reporting of studies devel-
oping, validating, or updating a predictionmodel, whether for diagnostic or prognostic purposes. This article describes how the TRIPODStatement
was developed. An extensive list of items based on a review of the literature was created, which was reduced after aWeb-based survey and revised
during a 3-daymeeting in June 2011withmethodologists, health care professionals, and journal editors. The listwas refinedduring severalmeetings
of the steering group and in e-mail discussions with thewider group of TRIPOD contributors. The resulting TRIPOD Statement is a checklist of 22
items, deemed essential for transparent reporting of a prediction model study. The TRIPOD Statement aims to improve the transparency of the re-
porting of a prediction model study regardless of the study methods used. The TRIPOD Statement is best used in conjunction with the TRIPOD
explanation and elaboration document. To aid the editorial process and readers of prediction model studies, it is recommended that authors include
a completed checklist in their submission (also available at www.tripod-statement.org).  2015TheAuthors. Published byElsevier Inc. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Editors’ Note: In order to encourage dissemination of
theTRIPODStatement, this article is freely accessible on
the Annals of Internal Medicine Web site (www.annals.
org) and will be also published in BJOG, British Journal
of Cancer, British Journal of Surgery, BMC Medicine,
British Medical Journal, Circulation, Diabetic Medicine,
European Journal of Clinical Investigation, European
Urology, and Journal of Clinical Epidemiology. The au-
thors jointly hold the copyright of this article. An accom-
panying Explanation and Elaboration article is freely
available only on www.annals.org; Annals of Internal
Medicine holds copyright for that article.
For contributors to the TRIPOD Statement, see the
Appendix (available at www.annals.org).In medicine, patients with their care providers are con-
fronted with making numerous decisions on the basis of an
estimated riskorprobability that a specific disease or condition* Corresponding author.
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0895-4356/ 2015TheAuthors. PublishedbyElsevier Inc. This is an open access aris present (diagnostic setting) or a specific event will occur in
the future (prognostic setting) (Fig. 1). In the diagnostic
setting, the probability that a particular disease is present can
be used, for example, to inform the referral of patients for
further testing, initiate treatment directly, or reassure patients
that a serious cause for their symptoms is unlikely. In the prog-
nostic setting, predictions can be used for planning lifestyle or
therapeutic decisions based on the risk for developing a partic-
ular outcome or state of health within a specific period [1,2].
Such estimates of risk can also be used to risk-stratify partici-
pants in therapeutic clinical trials [3,4].
In both the diagnostic and prognostic setting, estimates
of probabilities are rarely based on a single predictor [5].
Doctors naturally integrate several patient characteristics
and symptoms (predictors, test results) to make a prediction
(Fig. 2 for differences in common terminology between
diagnostic and prognostic studies). Prediction is therefore
inherently multivariable. Prediction models (also
commonly called ‘‘prognostic models,’’ ‘‘risk scores,’’ or
‘‘prediction rules’’ [6]) are tools that combine multiple pre-
dictors by assigning relative weights to each predictor to
obtain a risk or probability [1,2]. Well-known prediction
models include the Framingham Risk Score [7]; Ottawaticle under theCCBY license (http://creativecommons.org/licenses/by/4.0/).
 Type 1a Development of a prediction model where predictive performance is then directly evaluated using exactly the same data  (apparent performance).
 Type 1b Development of a prediction model using the entire data set, but then using resampling (e.g., bootstrapping or cross-validation) techniques to 
evaluate the performance and optimism of the developed model.  Resampling techniques, generally referred to as “internal validation”, are 
recommended as a prerequisite for prediction model development, particularly if data are limited (6, 14, 15).
 Type 2a The data are randomly split into 2 groups: one to develop the prediction model, and one to evaluate its predictive performance.  This design is 
generally not recommended or better than type 1b, particularly in case of limited data, because it leads to lack of power during model development 
and validation (14, 15, 16).
 Type 2b The data are nonrandomly split (e.g., by location or time) into 2 groups: one to develop the prediction model and one to evaluate its predictive 
performance.  Type 2b is a stronger design for evaluating model performance than type 2a, because allows for nonrandom variation between the 
2 data sets (6, 13, 17).
 Type 3 Development of a prediction model using 1 data set and an evaluation of its performance on separate data (e.g., from a different study).
 Type 4 The evaluation of the predictive performance of an existing (published) prediction model on separate data (13).
Types 3 and 4 are commonly referred to as “external validation studies.” Arguably type 2b is as well, although it may be considered an intermediary between 
internal and external validation.  
D
Type 4: Validation only
Type 3: Development and validation
using separate data
Type 2b: Nonrandom split-sample
development and validation
Type 2a: Random split-sample
development and validation
Analysis
Type
Description
D V
D V
V
Type 1b: Development and validation
using resampling
Type 1a: Development only
Only a single data set 
is available: All data 
are used to develop 
the model
Only a single data set 
is available: A portion 
of the data are used to
develop the model
 
  A separate data set is 
available for validation 
Fig. 1. Types of prediction model studies covered by the TRIPOD statement. D, development data; V, validation data.
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dex [10]; and the Simplified Acute Physiology Score [11].1. Prediction model studies
Prediction model studies can be broadly categorized as
model development [12]; model validation (with or without
updating) [13] or a combination of both (Fig. 3). Model
development studies aim to derive a prediction model by se-
lecting the relevant predictors and combining themstatistically into a multivariable model. Logistic and Cox
regression are most frequently used for short-term (for
example, disease absent vs. present, 30-day mortality) and
long-term (for example, 10-year risk) outcomes, respec-
tively [12e17]. Studies may also focus on quantifying the
incremental or added predictive value of a specific predictor
(for example, newly discovered) to a prediction model [18].
Quantifying the predictive ability of a model on the same
data from which the model was developed (often referred to
as apparent performance) will tend to give an optimistic es-
timate of performance, owing to overfitting (too few
Predictors:
Patient characteristics
(symptoms & signs)
Imaging tests
Laboratory tests
Others
Diagnostic multivariable modeling study
Subjects with presenting
symptoms
Outcome:
Disease present
or absent
Outcome:
Development
of event Y
Cross-sectional
relationship
Predictors:
Patient characteristics
Disease characteristics
Imaging tests
Laboratory tests
Others
Prognostic multivariable modeling study
Subjects in a
health state
T = 0
T = 0
Longitudinal
relationship
End of
follow-up
Y Y Y
Fig. 2. Schematic representation of diagnostic and prognostic prediction modeling studies. The nature of the prediction in diagnosis is estimating
the probability that a specific outcome or disease is present (or absent) within an individual, at this point in timedthat is, the moment of prediction
(T5 0). In prognosis, the prediction is about whether an individual will experience a specific event or outcome within a certain time period. In other
words, in diagnostic prediction the interest is in principle a cross-sectional relationship, whereas prognostic prediction involves a longitudinal rela-
tionship. Nevertheless, in diagnostic modeling studies, for logistical reasons, a time window between predictor (index test) measurement and the
reference standard is often necessary. Ideally, this interval should be as short as possible and without starting any treatment within this period.
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tors) and the use of predictor selection strategies [19].
Studies developing new prediction models should therefore
always include some form of internal validation to quantify
any optimism in the predictive performance (for example,
calibration and discrimination) of the developed model. In-
ternal validation techniques use only the original study sam-
ple and include such methods as bootstrapping or cross-
validation. Internal validation is a necessary part of model
development [2]. Overfitting, optimism, and miscalibration
may also be addressed and accounted for during the model
development by applying shrinkage (for example, heuristic
or based on bootstrapping techniques) or penalization proce-
dures (for example, ridge regression or lasso) [20].
After developing a prediction model, it is strongly rec-
ommended to evaluate the performance of the model in
other participant data than was used for the model develop-
ment. Such external validation requires that for each indi-
vidual in the new data set, outcome predictions are made
using the original model (that is, the published regression
formula) and compared with the observed outcomes
[13,14]. External validation may use participant data
collected by the same investigators, typically using the
same predictor and outcome definitions and measurements,but sampled from a later period (temporal or narrow valida-
tion); by other investigators in another hospital or country,
sometimes using different definitions and measurements
(geographic or broad validation); in similar participants
but from an intentionally different setting (for example,
model developed in secondary care and assessed in similar
participants but selected from primary care); or even in
other types of participants (for example, model developed
in adults and assessed in children, or developed for predict-
ing fatal events and assessed for predicting nonfatal events)
[13,15,17,21,22]. In case of poor performance, the model
can be updated or adjusted on the basis of the validation
data set [13].2. Reporting of multivariable prediction model studies
Studies developing or validating a multivariable predic-
tion model share specific challenges for researchers [6].
Several reviews have evaluated the quality of published re-
ports that describe the development or validation prediction
models [23e28]. For example, Mallett and colleagues [26]
examined 47 reports published in 2005 presenting new pre-
diction models in cancer. Reporting was found to be poor,
Despite the different nature (timing) of the prediction, there are many similarities between diagnostic and prognostic prediction models, including: 
• Type of outcome is often binary: either disease of interest present versus absent (in diagnosis) or the future occurrence of an event yes or no (in 
prognosis). 
• The key interest is to generate the probability of the outcome being present or occurring for an individual, given the values of 2 or more predictors, with 
the purpose of informing patients and guiding clinical decision making.
• The same challenges as when developing a multivariable prediction model, such as selection of the predictors, model-building strategies, and handling of 
continuous predictors and the danger of overfitting.
• The same measures for assessing model performance.
Different terms for similar features between diagnostic and prognostic modeling studies are summarized below.
Diagnostic Prediction Modeling Study
Diagnostic tests or index tests
Target disease/disorder (presence vs. absence)
Reference standard and disease verification
Partial verification
Explanatory variables, predictors, covariates (X variables)
Outcome (Y variable)
Missing outcomes
Prognostic Prediction Modeling Study
Prognostic factors or indicators
Event (future occurrence: yes or no)
Event definition and event measurement
Loss to follow-up and censoring
Fig. 3. Similarities and differences between diagnostic and prognostic prediction models.
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model development, from descriptions of patient data to
statistical modeling methods. Collins and colleagues [24]
evaluated the methodological conduct and reporting of 39
reports published before May 2011 describing the develop-
ment of models to predict prevalent or incident type 2 dia-
betes. Reporting was also found to be generally poor, with
key details on which predictors were examined, the
handling and reporting of missing data, and model-
building strategy often poorly described. Bouwmeester
and colleagues [23] evaluated 71 reports, published in
2008 in 6 high-impact general medical journals, and like-
wise observed an overwhelmingly poor level of reporting.
These and other reviews provide a clear picture that, across
different disease areas and different journals, there is a
generally poor level of reporting of prediction model
studies [6,23e27,29]. Furthermore, these reviews have
shown that serious deficiencies in the statistical methods,
use of small data sets, inappropriate handling of missing
data, and lack of validation are common [6,23e27,29].
Such deficiencies ultimately lead to prediction models that
are not or should not be used. It is therefore not surprising,
and fortunate, that very few prediction models, relative to
the large number of models published, are widely imple-
mented or used in clinical practice [6].
Prediction models in medicine have proliferated in
recent years. Health care providers and policy makers are
increasingly recommending the use of prediction models
within clinical practice guidelines to inform decision mak-
ing at various stages in the clinical pathway [30,31]. It is a
general requirement of reporting of research that otherresearchers can, if required, replicate all the steps taken
and obtain the same results [32]. It is therefore essential
that key details of how a prediction model was developed
and validated be clearly reported to enable synthesis and
critical appraisal of all relevant information [14,33e36].3. Reporting guidelines for prediction model studies:
the TRIPOD statement
We describe the development of the TRIPOD (Trans-
parent Reporting of a multivariable prediction model for In-
dividual Prognosis or Diagnosis) Statement, a guideline
specifically designed for the reporting of studies developing
or validating a multivariable prediction model, whether for
diagnostic or prognostic purposes. TRIPOD is not intended
for multivariable modeling in etiologic studies or for studies
investigating single prognostic factors [37]. Furthermore,
TRIPOD is also not intended for impact studies that quantify
the impact of using a prediction model on participant or doc-
tors’ behavior and management, participant health out-
comes, or cost-effectiveness of care, compared with not
using the model [13,38].
Reporting guidelines for observational (the STrengthening
the Reporting of OBservational studies in Epidemiology
[STROBE]) [39]; tumor marker (REporting recommenda-
tions for tumor MARKer prognostic studies [REMARK])
[37]; diagnostic accuracy (STAndards for the Reporting of
Diagnostic accuracy studies [STARD]) [40]; and genetic risk
prediction (Genetic RIsk Prediction Studies [GRIPS]) [41]
studies all contain many items that are relevant to studies
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these guidelines are entirely appropriate for prediction model
studies. The 2 guidelines most closely related to prediction
models are REMARK and GRIPS. However, the focus of
the REMARK checklist is primarily on prognostic factors
and not prediction models, whereas the GRIPS statement is
aimed at risk prediction using genetic risk factors and the spe-
cific methodological issues around handling large numbers of
genetic variants.
To address a broader range of studies, we developed the
TRIPOD guideline: Transparent Reporting of a multivari-
able prediction model for Individual Prognosis or Diagnosis.
TRIPOD explicitly covers the development and validation
of prediction models for both diagnosis and prognosis, for
all medical domains and all types of predictors. TRIPOD
also places much more emphasis on validation studies and
the reporting requirements for such studies. The reporting
of studies evaluating the incremental value of specific pre-
dictors, beyond established predictors or even beyond exist-
ing prediction models [18,42]; also fits entirely within the
remit of TRIPOD (see the accompanying explanation and
elaboration document [43]; available at www.annals.org).4. Developing the TRIPOD statement
We convened a 3-day meeting with an international
group of prediction model researchers, including statisti-
cians, epidemiologists, methodologists, health care profes-
sionals, and journal editors (from Annals of Internal
Medicine, BMJ, Journal of Clinical Epidemiology, and
PLoS Medicine) to develop recommendations for the
TRIPOD Statement.
We followed published guidance for developing report-
ing guidelines [44] and established a steering committee
(Drs. Collins, Reitsma, Altman, and Moons) to organize
and coordinate the development of TRIPOD. We conducted
a systematic search of MEDLINE, EMBASE, PsychINFO,
and Web of Science to identify any published articles mak-
ing recommendations on reporting of multivariable predic-
tion models (or aspects of developing or validating a
prediction model), reviews of published reports of multivar-
iable prediction models that evaluated methodological
conduct or reporting and reviews of methodological
conduct and reporting of multivariable models in general.
From these studies, a list of 129 possible checklist items
was generated. The steering committee then merged related
items to create a list of 76 candidate items.
Twenty-five experts with a specific interest in prediction
models were invited by e-mail to participate in the Web-
based survey and to rate the importance of the 76 candidate
checklist items. Respondents (24 of 27) included methodol-
ogists, health care professionals, and journal editors. (In
addition to the 25 meeting participants, the survey was also
completed by 2 statistical editors from Annals of Internal
Medicine.)The results of the survey were presented at a 3-day
meeting in June 2011, in Oxford, United Kingdom; it was at-
tended by 24 of the 25 invited participants (22 of whom had
participated in the survey). During the 3-day meeting, each
of the 76 candidate checklist items was discussed in turn,
and a consensus was reached on whether to retain, merge
with another item, or omit the item. Meeting participants
were also asked to suggest additional items. After the
meeting, the checklist was revised by the steering committee
during numerous face-to-face meetings, and circulated to the
participants to ensure it reflected the discussions. While
making revisions, conscious efforts were made to harmonize
our recommendations with other reporting guidelines, and
where possible we chose the same or similar wording for
items [37,39,41,45,46].5. TRIPOD components
The TRIPOD Statement is a checklist of 22 items that
we consider essential for good reporting of studies devel-
oping or validating multivariable prediction models
(Table 1). The items relate to the title and abstract (items
1 and 2), background and objectives (item 3), methods
(items 4 through 12), results (items 13 through 17), discus-
sion (items 18 through 20), and other information (items 21
and 22). The TRIPOD Statement covers studies that report
solely development [12,15]; both development and external
validation, and solely external validation (with or without
updating), of a prediction model [14] (Fig. 3). Therefore,
some items are relevant only for studies reporting the devel-
opment of a prediction model (items 10a, 10b, 14, and 15),
and others apply only to studies reporting the (external)
validation of a prediction model (items 10c, 10e, 12, 13c,
17, and 19a). All other items are relevant to all types of pre-
diction model development and validation studies. Items
relevant only to the development of a prediction model
are denoted by D, items relating solely to a validation of
a prediction model are denoted by V, whereas items relating
to both types of study are denoted D;V.
The recommendations within TRIPOD are guidelines
only for reporting research and do not prescribe how to
develop or validate a prediction model. Furthermore, the
checklist is not a quality assessment tool to gauge the qual-
ity of a multivariable prediction model.
An ever-increasing number of studies are evaluating the
incremental value of specific predictors, beyond established
predictors or even beyond existing prediction models
[18,42]. The reporting of these studies fits entirely within
the remit of TRIPOD (see accompanying explanation and
elaboration document [43]).6. The TRIPOD explanation and elaboration
document
In addition to the TRIPOD Statement, we produced a sup-
porting explanation and elaboration document [43] in a
Table 1. Checklist of items to include when reporting a study developing or validating a multivariable prediction model for diagnosis or prognosisa
Section/Topic Item
Development
or validation? Checklist item Page
Title and abstract
Title 1 D; V Identify the study as developing and/or validating a multivariable prediction
model, the target population, and the outcome to be predicted.
Abstract 2 D; V Provide a summary of objectives, study design, setting, participants,
sample size, predictors, outcome, statistical analysis, results, and
conclusions.
Introduction
Background and objectives 3a D; V Explain the medical context (including whether diagnostic or prognostic)
and rationale for developing or validating the multivariable prediction
model, including references to existing models.
3b D; V Specify the objectives, including whether the study describes the
development or validation of the model, or both.
Methods
Source of data 4a D; V Describe the study design or source of data (eg, randomized trial, cohort, or
registry data), separately for the development and validation data sets, if
applicable.
4b D; V Specify the key study dates, including start of accrual; end of accrual; and,
if applicable, end of follow-up.
Participants 5a D; V Specify key elements of the study setting (eg, primary care, secondary care,
general population) including number and location of centers.
5b D; V Describe eligibility criteria for participants.
5c D; V Give details of treatments received, if relevant.
Outcome 6a D; V Clearly define the outcome that is predicted by the prediction model,
including how and when assessed.
6b D; V Report any actions to blind assessment of the outcome to be predicted.
Predictors 7a D; V Clearly define all predictors used in developing the multivariable prediction
model, including how and when they were measured.
7b D; V Report any actions to blind assessment of predictors for the outcome and
other predictors.
Sample size 8 D; V Explain how the study size was arrived at.
Missing data 9 D; V Describe how missing data were handled (eg, complete-case analysis,
single imputation, multiple imputation) with details of any imputation
method.
Statistical analysis methods 10a D Describe how predictors were handled in the analyses.
10b D Specify type of model, all model-building procedures (including any
predictor selection), and method for internal validation.
10c V For validation, describe how the predictions were calculated.
10d D; V Specify all measures used to assess model performance and, if relevant, to
compare multiple models.
10e V Describe any model updating (eg, recalibration) arising from the validation,
if done.
Risk groups 11 D; V Provide details on how risk groups were created, if done.
Development vs. validation 12 V For validation, identify any differences from the development data in
setting, eligibility criteria, outcome, and predictors.
Results
Participants 13a D; V Describe the flow of participants through the study, including the number of
participants with and without the outcome and, if applicable, a summary
of the follow-up time. A diagram may be helpful.
13b D; V Describe the characteristics of the participants (basic demographics,
clinical features, available predictors), including the number of
participants with missing data for predictors and outcome.
13c V For validation, show a comparison with the development data of the
distribution of important variables (demographics, predictors and
outcome).
Model development 14a D Specify the number of participants and outcome events in each analysis.
14b D If done, report the unadjusted association between each candidate
predictor and outcome.
Model specification 15a D Present the full prediction model to allow predictions for individuals (ie, all
regression coefficients, and model intercept or baseline survival at a
given time point).
15b D Explain how to the use the prediction model.
(Continued )
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Table 1. Continued
Section/Topic Item
Development
or validation? Checklist item Page
Model performance 16 D; V Report performance measures (with CIs) for the prediction model.
Model updating 17 V If done, report the results from any model updating (ie, model specification,
model performance).
Discussion
Limitations 18 D; V Discuss any limitations of the study (such as nonrepresentative sample, few
events per predictor, missing data).
Interpretation 19a V For validation, discuss the results with reference to performance in the
development data, and any other validation data.
19b D; V Give an overall interpretation of the results, considering objectives,
limitations, results from similar studies, and other relevant evidence.
Implications 20 D,V Discuss the potential clinical use of the model and implications for future
research.
Other information
Supplementary information 21 D; V Provide information about the availability of supplementary resources, such
as study protocol, Web calculator, and data sets.
Funding 22 D; V Give the source of funding and the role of the funders for the present study.
a Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are
denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD explanation
and elaboration document.
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Each checklist item is explained and accompanied by exam-
ples of good reporting from published articles. In addition,
because many such studies are methodologically weak, we
also summarize the qualities of good (and the limitations
of less good) studies, regardless of reporting [43]. A compre-
hensive evidence base from existing systematic reviews of
prediction models was used to support and justify the ratio-
nale for including and illustrating each checklist item. The
development of the explanation and elaboration document
was completed after several face-to-face meetings, telecon-
ferences, and iterations among the authors. Additional revi-
sions were made after sharing the document with the whole
TRIPOD group before final approval.7. Role of the funding source
There was no explicit funding for the development of this
checklist and guidance document. The consensus meeting in
June 2011 was partially funded by a National Institute for
Health Research Senior Investigator Award held by Dr. Alt-
man, Cancer Research UK, and the Netherlands Organiza-
tion for Scientific Research. Drs. Collins and Altman are
funded in part by the Medical Research Council. Dr. Altman
is a member of the Medical Research Council Prognosis
Research Strategy (PROGRESS) Partnership. The funding
sources had no role in the study design, data collection, anal-
ysis, preparation of the manuscript, or decision to submit the
manuscript for publication.8. Discussion
Many reviews have showed that the quality of reporting
in published articles describing the development orvalidation of multivariable prediction models in medicine
is poor [23e27,29]. In the absence of detailed and trans-
parent reporting of the key study details, it is difficult for
the scientific and health care community to objectively
judge the strengths and weaknesses of a prediction model
study [34,50,51]. The explicit aim of this checklist is to
improve the quality of reporting of published prediction
model studies. The TRIPOD guideline has been developed
to support authors in writing reports describing the develop-
ment, validation or updating of prediction models, aid edi-
tors and peer reviewers in reviewing manuscripts submitted
for publication, and help readers in critically appraising
published reports.
The TRIPOD Statement does not prescribe how studies
developing, validating, or updating prediction models
should be undertaken, nor should it be used as a tool for
explicitly assessing quality or quantifying risk of bias in
such studies [52]. There is, however, an implicit expectation
that authors have an appropriate study design and conducted
certain analyses to ensure all aspects of model development
and validation are reported. The accompanying explanation
and elaboration document describes aspects of good practice
for such studies, as well as highlighting some inappropriate
approaches that should be avoided [43].
TRIPOD encourages complete and transparent reporting
reflecting study design and conduct. It is a minimum set
of information that authors should report to inform the
reader about how the study was carried out. We are not
suggesting a standardized structure of reporting, rather that
authors should ensure that they address all the checklist
items somewhere in their article with sufficient detail and
clarity.
We encourage researchers to develop a study protocol,
especially for model development studies, and even register
their study in registers that accommodate observational
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tance of also publishing protocols for developing or vali-
dating prediction models, certainly when conducting a
prospective study, is slowly being acknowledged [55,56].
Authors can also include the study protocol when submit-
ting their article for peer review, so that readers can know
the rationale for including individuals into the study or
whether all of the analyses were prespecified.
To help the editorial process; peer reviewers; and, ulti-
mately, readers, we recommend submitting the checklist
as an additional file with the report, indicating the pages
where information for each item is reported. The TRIPOD
reporting template for the checklist can be downloaded
from www.tripod-statement.org.
Announcements and information relating to TRIPOD will
be broadcast on the TRIPOD Twitter address (@TRIPOD-
Statement). The Enhancing the QUAlity and Transparency
Of health Research (EQUATOR) Network (www.equator-
network.org) will help disseminate and promote the TRIPOD
Statement.
Methodological issues in developing, validating, and up-
dating prediction models evolve. TRIPOD will be periodi-
cally reappraised, and if necessary modified to reflect
comments, criticisms, and any new evidence. We therefore
encourage readers to make suggestions for future updates
so that ultimately, the quality of prediction model studies
will improve.
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